Search research articles
Contact Us
Filters
Showing results (161-170 of 187) with videos related to
Page
of 19
Sort By:
Blood Advances
|
April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy
Zoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Blood
|
June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The New England Journal of Medicine
|
November 6, 2024
Randomized Trial of Very Early Medication Abortion
Karin Brandell, Tagrid Jar-Allah, John Reynolds-Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
Blood
|
August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
David T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
January 15, 2023
Mitochondria-containing extracellular vesicles (EV) reduce mouse brain infarct sizes and EV/HSP27 protect ischemic brain endothelial cultures
Kandarp M Dave, Donna B Stolz, Venugopal R Venna, et al.
The Lancet. Haematology
|
December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
Harry J Iland, Marnie Collins, Ken Bradstock, et al.
The New England Journal of Medicine
|
June 13, 2025
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
David J Curtis, Sushrut S Patil, John Reynolds, et al.
Blood Advances
|
January 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL
Harry J Iland, John Reynolds, Alan V Boddy, et al.
Blood Advances
|
March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Sara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 187) with videos related to
Sort By:
Page
of 19
Blood Advances
|
April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy
Zoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Blood
|
June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The New England Journal of Medicine
|
November 6, 2024
Randomized Trial of Very Early Medication Abortion
Karin Brandell, Tagrid Jar-Allah, John Reynolds-Wright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
Blood
|
August 5, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
David T Yeung, Naranie Shanmuganathan, John Reynolds, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
January 15, 2023
Mitochondria-containing extracellular vesicles (EV) reduce mouse brain infarct sizes and EV/HSP27 protect ischemic brain endothelial cultures
Kandarp M Dave, Donna B Stolz, Venugopal R Venna, et al.
The Lancet. Haematology
|
December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
Harry J Iland, Marnie Collins, Ken Bradstock, et al.
The New England Journal of Medicine
|
June 13, 2025
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
David J Curtis, Sushrut S Patil, John Reynolds, et al.
Blood Advances
|
January 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL
Harry J Iland, John Reynolds, Alan V Boddy, et al.
Blood Advances
|
March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Sara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Page
of 19